ViroPharma Prescribes $8M To Cure Investor Suit
A class of ViroPharma Inc. shareholders claiming the company intentionally misled investors regarding market exclusivity for its signature gastrointestinal antibiotic asked a Pennsylvania federal judge Wednesday to approve an $8 million...To view the full article, register now.
Already a subscriber? Click here to view full article